There is increasing evidence that common genetic variants can contribute to general immune dysregulation and susceptibility to noninfectious inflammatory diseases.
The cytotoxic T-lymphocyte-associated protein 4 (CTLA4) has been associated with Graves disease, type 1 diabetes (T1D), Addison's disease, celiac disease and rheumatoid arthritis (RA) with odds ratios (ORs) ranging from 1.1 to 1.5 (1) . In addition, a missense SNP, rs2476601, in the intracellular tyrosine phosphatase, PTPN22, has been found to be a risk factor (OR = 1.4-2.0) for a number of autoimmune diseases including RA, T1D, autoimmune thyroid disease and systemic lupus erythematosis (SLE) (1) while variants in the third intron of the transcription factor, STAT4, have been associated with risk to both RA and SLE (OR = 1.2-1.8) (2) . Finally, the recent plethora of whole genome association (WGA) publications suggests common variants in other genes such as PTPN2 and IL2RA may contribute to risk of multiple noninfectious inflammatory diseases (3, 4) .
We recently found that common haplotypes in both IL12B and IL23R, marked by the IL12B SNPs rs3212227 and rs6887695 and the IL23R SNPs rs7530511 and rs11209026, were associated with psoriasis (odds ratios 1.4-1.5) (5) and association of these genes with psoriasis has now been replicated in another studies (6, 7) .
Independently, Duerr and colleagues (8) , and subsequently others (3, 9) , have shown that the IL23R SNP, rs11209026, which encodes an arginine to glutamine change at position 381, was also strongly associated with inflammatory bowel disease (IBD) (OR = 2.2-3.8).
Interestingly, the psoriasis-associated IL12B SNP, rs6887695, has also been associated with Crohn's Disease (CD) (9) and a large association scan of 14,500 nonsynonymous SNPs has identified the IL23R missense SNP, rs11209026, as a risk factor for ankylosing spondylitis (AS) (10) . T cells that appear to play a fundamental role in autoimmunity.
The aim of this study was to determine whether the IL12B and IL23R SNPs associated with psoriasis and other noninfectious inflammatory diseases were also associated with RA and/or specific subphenotypes of this disease by genotyping the four implicated SNPs (rs3212227, rs6887695, rs7530511 and rs11209026) in three large, independent, white RA case-control sample sets (1732 cases/2502 controls). All cases included in this study were white, met the 1987 American College of Rheumatology diagnostic criteria (12) and have been described in detail elsewhere (13, 14) . Information on carriage of the PTPN22 C1858T risk allele was available for all three sample sets. Complete information on HLA-DRB1 shared epitope (SE) status was available for sample sets 1 and 2.
Sample set 1 was genotyped using a multiplexed conventional polymerase chain reaction followed by a flow cytometry-based oligonucleotide ligation assay (15); sample sets 2 and 3 were genotyped for all four SNPs using kinetic PCR with allele-specific primers (16); (primer and probe sequences are available upon request). Genotypes were automatically called using custom software followed by hand curation without knowledge of case-control status. Previous cross-validation studies of these two platforms suggest a genotyping concordance of greater than 99.8% (5) . Carriage of the HLA-DRB1 SE was determined as previously described (13) .
An exact test of Hardy Weinberg Equilibrium (HWE) on the genotypic data, performing the analysis separately for cases and controls in each sample set, provided no evidence for deviation from HWE at any of the four SNPs tested (all P-values≥0.05) ( Table 1 ). Case and control allele frequencies for all four SNPs were similar across all three studies and in agreement with control frequencies from three white, North
American psoriasis case-control sample sets (5) . No significant association between any of the four SNPs and RA was detected by either allelic or genotypic analyses (Table 1) .
Stratifying by the presence of RF, gender, age of onset, carriage of HLA-DRB1 SE positive alleles or carriage of the known PTPN22 1858T risk allele also revealed no consistent evidence for association across sample sets (data not shown).
Power to detect a disease model with a continuity-corrected Mantel-Haenszel test (17) on allelic data was determined for each SNP using a Monte Carlo simulation (10,000
replicates for each data point) with the significance level set at alpha = 0.05 for all runs.
Simulations were performed to estimate the disease model allelic OR necessary to achieve 80% power given the observed allele frequencies and sample sizes in our RA data sets. These results indicate we had 80% power to detect allelic odds ratios of 1.17 for rs3212227, 1.14 for rs6887695, 1.21 for rs7530511 and 1.27 for rs11209026.
Two SNP haplotypes were estimated for each gene ( showing that rs7530511 and the rs7530511-rs11209026 haplotypes do not appear to be associated with RA.
Since inflammatory diseases associated with the same genetic variant may share a common underlying mechanism, a thorough understanding of the diseases associated with a particular variant may shed light on disease pathogenesis. Consequently, the finding that a subset of psoriasis-associated IL12B and IL23R SNPs are also associated with CD and AS led us to carefully evaluate the role of these same SNPs in other inflammatory diseases. We recently reported the results of a well-powered, family-based association analysis of 910 multiple sclerosis (MS) nuclear families (3132 individuals) which provided no evidence that any of these four SNPs were associated with MS risk, even after the data were stratified by sex of the patient, presence/absence of the risk HLA-DRB1*1501 allele, and disease severity (22) . Our analyses of three RA case-control sample sets (1732 cases / 2502 controls) presented here suggest that there is also no evidence of association between these same SNPs/haplotypes and RA, even after the data were stratified for sex of the patient, age of disease onset, presence/absence of the risk HLA-DRB1 SE, presence/absence of the risk PTPN22 1858T allele, and RF-status. These studies were well powered to detect modest effect sizes allowing us to rule out strong RA effects at these four SNPs; however, it is still possible that these SNPs could play a minor role in risk for RA. This will be uncovered by using much larger sample sets. 
